profit from every $100 of sales.
$0$100
Astrana Health
$33.77-2.12% today
+32.2% in 1 year
1-year low $18.161-year high $49.81
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $74.59 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Astrana Health sold, what it kept, and what it did with the cash.
Sales went from $1.14 billion in 2022 to $3.18 billion in 2025, with $22.5 million of profit last year.
SalesProfit
Astrana Health handed back 22% of the cash it generated last year.
Buybacks $15M$8M
Free cash flow 2025$104M
Bought back its own shares$15M
Paid as dividends$8M
Cash vs. debt$429M vs. $1.1B
Astrana Health vs. similar companies
Astrana Health grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Astrana Health | 74.6× · Very expensive | ||
 Tenet Healthcare | 16.3× · Fair price | ||
 Solventum | 9.9× · Cheap | ||
 Encompass Health | 24.5× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.8× · Cheap |
AI analysis
An AI analyst reads Astrana Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,144 | 1,387 | 2,035 | 3,182 | |
| 199 | 215 | 271 | 342 | |
| 104 | 85 | 89 | 79 | |
| 112 | 124 | 142 | 135 | |
| 45 | 61 | 43 | 22 | |
| 1.08 | 1.29 | 0.90 | 0.46 | |
| 17.4% | 15.5% | 13.3% | 10.7% | |
| 9.1% | 6.1% | 4.4% | 2.5% | |
| 3.9% | 4.4% | 2.1% | 0.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 966 | 933 | 1,355 | 2,219 |
| Cash | 288 | 294 | 288 | 429 |
| Total debt | 229 | 321 | 471 | 1,078 |
| Total liabilities | 408 | 523 | 841 | 1,660 |
| 543 | – | – | – | |
| 45 | 47 | 48 | 49 | |
| 9.7% | – | – | – | |
| 8.3% | – | – | – |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 82 | 68 | 52 | 115 | |
| 23 | 29 | 8 | 10 | |
| 59 | 40 | 44 | 104 | |
| Dividends paid | 14 | 62 | 4 | 8 |
| 9 | 10 | 1 | 15 | |
| 16 | 22 | 35 | 39 |
Valuation
- 74.6×
- 27.3×
- –
- 2.3×
- 0.5×
- 16.1×
- 17.2×
- 6.2%
- 1.3%
- 0.0%
Profitability
- 10.7%
- 2.5%
- 0.7%
- 4.2%
- 3.2%
- 5.6%
- 3.9%
- 1.3%
- 5.4%
- –
Growth
- +40.6%
- −24.8%
- +136.6%
- –
- +2.9%
Financial health
- 3.9×
- 1.33
- 45.2%
- 1.5×
- 1.35
- 1.35
- 1.50
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 44%of 948
Bottom 34%of 871
Bottom 13%of 560
Top 15%of 868
Top 15%of 985
What analysts expect
- Average price target
- $34.20
- Range
- $26.00 – $40.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.74 | 0.29 | +155.2% |
| Mar 2, 2026 | 0.54 | 0.15 | +260.0% |
| Nov 6, 2025 | 0.01 | 0.47 | −97.9% |
| Aug 7, 2025 | 0.19 | 0.36 | −47.2% |
| May 8, 2025 | 0.14 | 0.23 | −39.1% |
| Feb 27, 2025 | -0.15 | 0.22 | −168.2% |
| Nov 7, 2024 | 0.33 | 0.32 | +3.1% |
| Aug 7, 2024 | 0.40 | 0.39 | +2.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
36No pass
Philip Fisher
15No pass
Peter Lynch
35No pass
Joel Greenblatt
8No pass
Charlie Munger
4No pass
Terry Smith
14No pass
Questions about Astrana Health
Is Astrana Health a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Astrana Health AI analysis
What does Astrana Health do?
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. It is in Medical - Care Facilities.
Does Astrana Health pay a dividend?
Yes. In 2025 it paid out $7.89 million in dividends.
Is Astrana Health stock halal?
No. Astrana Health does not pass our halal screen: its debt is 64% of its market value, at or above the 33% limit. How we check
How has Astrana Health stock done over the past year?
Up 32.2% over the past twelve months, to $33.77. It traded between $18.16 and $49.81 and is 32.2% below its high.
Who are Astrana Health's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with Astrana Health's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.